The CheckMate 9LA Trial for Stage IV/Recurrent Non-Small Cell Lung Cancer

Videos

Rapid Readouts: CheckMate 9LA

Martin Reck, MD, PhD, head of the department of thoracic oncology at Lung Clinic Grosshansdorf, discusses the rationale for the IMpower150 study, which assessed the combination of atezolizumab (Tecentriq), bevacizumab (Avastin), and chemotherapy in the first-line treatment of patients with nonsquamous non—small-cell lung cancer (NSCLC).

This trial was unique, explains Reck, in that it investigated a unique combination comprised of a checkpoint inhibitor, chemotherapy, and an antiangiogenic compound on the basis of the idea that the antiangiogenic compound combined with a checkpoint inhibitor could enhance the efficacy of immunotherapy.

Patients were randomized to receive either the standard of care or the combination therapy. In patients who received the combination, a significant and relevant improvement in progression-free survival and overall survival was been observed in the intent-to-treat population, says Reck. The trial was also notable for its inclusion of patients with pretreated 

Martin Reck, MD, PhD, head of the department of thoracic oncology at Lung Clinic Grosshansdorf, discusses the rationale for the IMpower150 study.

Dr. Reck on the Rationale of the Impower150 Study

Martin Reck, MD, PhD, Head of Thoracic Oncology, Hospital Grosshansdorf, discusses the maximum severity score (MSS) of baseline patient-reported Lung Cancer Symptom Scale (LCSS) as a prognostic and predictive factor for overall survival (OS) for patients with non-small cell lung cancer (NSCLC) treated with necitumumab in the phase III SQUIRE study.

The randomized phase III study examined the addition of necitumumab to gemcitabine-cisplatin in patients with stage IV squamous NSCLC. Data showed a significance increase in progression-free survival and OS. Researchers also sought to determine if the combination had an impact on quality of life, symptoms, and if symptoms would affect the drug's efficacy. This was conducted using the LCSS.

Reck says the study showed that there was a correlation with patient prognosis, explaining that patients who are symptomatic have a poorer prognosis. Researchers also used the MSS to determine if there was a correlation between treatment and the severity of patient symptoms. The best therapeutic impact was seen in patients with a worse symptomatic presentation and the highest severity at baseline, he adds.

View more from the 2015 ASCO Annual Meeting

Martin Reck, MD, PhD, Head of Thoracic Oncology, Hospital Grosshansdorf, discusses the maximum severity score (MSS) of baseline patient-reported Lung Cancer Symptom Scale (LCSS) as a prognostic and predictive factor for overall survival (OS) in the phase III SQUIRE study.


Martin Reck, MD, PhD, Lung Clinic Grosshansdorf

Articles

Rapid Readouts: CheckMate 9LA

Dr. Reck on the Rationale of the Impower150 Study

Dr. Reck Discusses Prognostic and Predictive Factors for OS With Necitumumab in NSCLC